GLP-1 for Weight Loss Market

The global GLP-1 for weight loss market was valued at USD 29.5 billion in 2025 and is estimated at USD 34.0 billion in 2026. The market is projected to reach USD 95.0 billion by 2034, representing a 13.7% CAGR during 2026–2034.

The market covers glucagon-like peptide-1 receptor agonists and GLP-1-based multi-agonists prescribed for chronic weight management, including semaglutide, tirzepatide, liraglutide and the newer oral agents. Revenue is counted where the product is labelled or reimbursed for obesity or overweight with comorbidities, so diabetes-only brands such as Ozempic and U.S. Mounjaro fall outside the boundary, while compounded copies are excluded because they are not approved medicines.

Demand rests on a very large untreated population. WHO estimates that 2.6 billion adults were overweight in 2024, including 940 million living with obesity, yet only a small fraction receive pharmacotherapy. That gap explains why prescription growth has outpaced manufacturing capacity for much of the past three years and why supply expansion, rather than physician demand, has often set the pace of revenue.

Commercial scale is now visible in company reporting. Novo Nordisk recorded Wegovy sales of DKK 79.1 billion in 2025, while Eli Lilly reported Zepbound revenue of USD 13.5 billion, up 175%. Both franchises are moving from list-price, insurer-dependent access toward self-pay, direct-to-patient and government price agreements, which widens volume but lowers revenue per prescription.

The next growth phase is being shaped by oral therapy and cardiometabolic outcome evidence. The FDA approved the Wegovy pill in December 2025 and Lilly's orforglipron, marketed as Foundayo, in April 2026, giving prescribers needle-free options that are easier to manufacture at scale and better suited to primary care and maintenance treatment.

Source: World Health Organization; CDC NCHS; Novo Nordisk FY2025 report; Eli Lilly Q4 2025 results.

The study assesses prescription GLP-1-based therapies used for chronic weight management in adults and adolescents, measured as manufacturer revenue across injectable and oral formats, care settings and product life-cycle stages.

Obesity prevalence keeps the eligible pool far larger than treated volume

The commercial case starts with epidemiology. CDC data show adult obesity in the United States at 40.3% for August 2021–August 2023, with severe obesity affecting 9.4% of adults. Because the FDA labels cover adults with a BMI of 30 or more, and those with a BMI of 27 plus a weight-related condition, tens of millions of Americans already qualify. Even after rapid uptake, treated patients remain a single-digit share of the eligible population, so prescription volume can keep compounding for years without saturating demand.

Cardiovascular outcome evidence turns weight loss into risk reduction

Payers have historically treated obesity drugs as lifestyle products. The SELECT trial changed that framing: in 17,604 adults with established cardiovascular disease and no diabetes, semaglutide cut major adverse cardiovascular events by 20% over a mean 40 months. That outcome supported a cardiovascular label for Wegovy and gave insurers a clinical rationale to cover therapy for higher-risk members. The practical effect is a shift from discretionary spending toward reimbursable disease management, which stabilizes long-term persistence and refill revenue.

Supply expansion converts latent demand into revenue

For much of 2022–2024, revenue was capped by pen-filling and active-ingredient capacity rather than physician demand. Lilly is building a USD 6 billion active-ingredient plant in Alabama alongside new oral and injectable sites, while Novo Nordisk has scaled fill-finish to reach 3.6 million obesity patients in 2025. As capacity loosens, manufacturers can open lower-priced vial and pill formats without rationing, allowing volume rather than allocation to set the growth rate. Capacity also lowers launch risk for new doses and international markets.

Price compression restrains revenue per patient

Value growth is lagging prescription growth because net prices are falling. Lilly reported that fourth-quarter 2025 realized prices declined 5% globally and 7% in the United States, while Novo Nordisk guided 2026 adjusted sales to a decline of 5% to 13% at constant exchange rates. Direct-to-consumer cash offers, government agreements and generic semaglutide entry in several countries all reduce average selling prices, so the market increasingly depends on new patients rather than price to expand revenue.

Compounded and gray-market copies divert paying patients

After the FDA moved semaglutide to resolved shortage status on 21 February 2025, enforcement discretion for 503B outsourcing facilities ended in May 2025. Novo Nordisk nevertheless reported that compounded semaglutide volume continued at broadly unchanged levels into early 2026. Telehealth platforms marketing personalized doses at low monthly prices keep pulling self-paying patients away from approved products, eroding branded share in the most price-sensitive cash segment and complicating persistence tracking. Lower branded cash prices are the industry's main counter-measure.

Sources: CDC NCHS; ACC summary of SELECT; Eli Lilly; Novo Nordisk; McDermott Will & Schulte.

Oral GLP-1 launches open primary-care and maintenance use

The FDA approved the 25 mg Wegovy pill on 22 December 2025, and it delivered 13.6% mean weight loss versus 2.2% for placebo at week 64. Lilly's Foundayo followed on 1 April 2026, achieving 12.4% weight loss among adherent participants in ATTAIN-1. Small-molecule orforglipron needs no cold chain or injection device, which lowers manufacturing cost and suits long-term maintenance after an injectable induction phase. Oral agents are therefore expected to widen the prescriber base well beyond obesity specialists.

Self-pay and direct-to-patient channels reshape distribution

Manufacturers now sell directly to consumers through LillyDirect, NovoCare and the TrumpRx portal. Under the November 2025 White House agreement, injectable prices on TrumpRx start at USD 350 per month and trend toward USD 245, while starting doses of the oral agents are offered at USD 145. By January 2026, about 70,000 of 230,000 weekly U.S. Wegovy prescriptions were self-pay. This channel bypasses pharmacy-benefit restrictions and creates a transparent price floor that insurers and employers now benchmark against.

Higher-efficacy multi-agonists raise the clinical bar

Head-to-head evidence is moving the market toward stronger agents. In SURMOUNT-5, tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks, results published in the New England Journal of Medicine in May 2025. Triple agonists such as retatrutide, amylin combinations and monthly dosing candidates are extending that efficacy race, which favors companies able to differentiate on magnitude of weight loss, lean-mass preservation and dosing convenience. Superior efficacy also strengthens negotiating power with payers that restrict formularies.

Patent expiries create low-cost generic semaglutide markets

Core semaglutide patents lapsed in India on 20 March 2026, and more than 50 brands from over 40 companies were expected to follow. Canada approved Apotex's generic Wegovy, branded Sevmia, on 29 June 2026, and Brazil authorized a domestic semaglutide generic for diabetes, but not obesity, in August 2026. Patent expiries by the end of 2026 cover countries holding 48% of the global obesity burden, pointing to sharp volume growth at much lower unit prices across emerging markets, along with new export opportunities for generic producers.

Public payers begin covering obesity treatment

Coverage is widening beyond employer plans, which had carried most of the reimbursed volume. England's NHS started funding tirzepatide through GP practices in mid-2025, with a first cohort of 220,000 patients planned over three years, while eligible U.S. Medicare members gained access to qualifying oral and injectable GLP-1 therapy for a USD 50 copay from July 2026. Public coverage raises long-run volume and persistence but comes with negotiated prices and eligibility rules that prioritize patients with the highest BMI and comorbidity burden, so uptake will build in waves.

The treatment landscape has moved from daily liraglutide to weekly semaglutide and tirzepatide, and now to oral and multi-agonist options. Each step has lifted average weight loss, broadened eligible indications and shifted prescribing from specialist bariatric programs toward primary care, endocrinology and digital health clinics.

Prescribing increasingly follows a sequence rather than a single product choice. Clinicians commonly start patients on a weekly injectable to achieve maximum loss, then consider a lower-cost oral agent or reduced dose for maintenance, because discontinuation is followed by substantial weight regain. That pathway lengthens treatment duration and makes persistence, tolerability and price the decisive variables for lifetime patient value.

Guideline support is also strengthening. WHO issued its first guideline on GLP-1 medicines for obesity in December 2025, conditionally recommending liraglutide, semaglutide and tirzepatide for long-term adult treatment alongside behavioral support. Professional endorsement of obesity as a chronic, relapsing disease reinforces the case for continuous therapy, while gastrointestinal side effects and muscle-mass concerns remain the main clinical reasons for dose reduction or treatment interruption.

Indication expansion is a further lever for prescribing growth. Tirzepatide already carries a U.S. label for obstructive sleep apnea in adults with obesity, and semaglutide's cardiovascular label broadens its use among patients with heart disease. Each new indication brings additional specialists, such as cardiologists and sleep physicians, into the prescriber base and strengthens payer justification for coverage.

By type, the GLP-1 for weight loss market is segmented into Injection and Oral Agent. Weekly subcutaneous pens and vials generated almost all base-year revenue, while oral agents became commercially meaningful only after the U.S. approvals of December 2025 and April 2026. The balance between the two formats is the clearest indicator of how quickly treatment moves into primary care.

Format mix will shift steadily toward tablets, yet injectables should retain value leadership because the highest-efficacy multi-agonists and monthly candidates in development are injectable molecules. Device innovation, including multi-dose pens and vials, will also help injectables defend volume in self-pay channels.

By application, the market is analyzed across Woman, Man, Adolescents and Others, with Others representing adults aged 65 and over. Patient mix reflects both clinical eligibility and differences in treatment-seeking behavior and insurance access.

By end user, the market is segmented into Hospitals, Specialty Clinics and Retail Pharmacies. Channel choice depends on where therapy is initiated, monitored and dispensed, and is shifting quickly as direct-to-consumer sales mature. Payer rules on who may initiate therapy also influence where patients are treated.

Through 2034, value is expected to remain pharmacy-led, while specialty clinics capture incremental initiation volume and hospitals focus on complex patients. Telehealth-linked clinics that bundle prescribing, coaching and pharmacy delivery are expected to be the most dynamic sub-channel, particularly in the United States and the United Kingdom.

By prescription status, the market is divided into Branded Pharmaceuticals, Generic/Biosimilar and Pipeline Drugs. This lens tracks how revenue migrates as patents expire and next-generation agents reach patients. It is the most useful lens for assessing long-term price erosion by country.

Branded therapies will still dominate value in 2034, but pricing power will depend on demonstrating superior efficacy or outcomes over low-cost generic semaglutide. Generic/Biosimilar revenue should rise fastest outside the United States, while Pipeline Drugs become a material revenue contributor once triple agonists and amylin combinations reach launch.

Regional demand reflects obesity prevalence, payer willingness to fund chronic weight management, patent status and the depth of self-pay channels. North America leads on value, while Asia-Pacific and Latin America are positioned for the fastest volume growth as generic semaglutide spreads.

Market access has become the single largest determinant of revenue per patient. Over 2025–2026, U.S. policy shifted from no Medicare coverage for weight-loss drugs toward negotiated prices, copay caps and transparent cash prices, while national health systems elsewhere began phased funding.

The November 2025 White House agreements with Lilly and Novo Nordisk set a framework for wider access, followed by the Medicare GLP-1 Bridge for qualifying Part D beneficiaries in July 2026, in exchange for sharply lower prices. For manufacturers, the trade-off is attractive only if volume growth offsets lower revenue per patient, which is why both companies are expanding capacity and oral supply in parallel.

Employer coverage remains the swing factor in the commercial market. Many plans restrict obesity drugs to patients with comorbidities or require lifestyle program enrollment, and some have dropped coverage because of budget impact. Transparent cash prices reduce that leverage, since patients can now buy approved therapy directly at prices close to what many plans pay after rebates.

Outside the United States, generic semaglutide is the most powerful access lever. Obesity-specific generics in India and Canada are pushing monthly costs down by well over half, and WHO has called for pooled procurement, tiered pricing and voluntary licensing so that low- and middle-income countries are not left behind. Tiered pricing would let manufacturers protect high-income margins while opening volume elsewhere.

Source: PharmExec; CMS; WHO guideline.

Regulatory and patent events are now resetting the market every few months. Approvals of oral agents widen the treatable population, while patent expiries in large emerging markets introduce generic competition years before U.S. exclusivity ends.

The pipeline is crowded and increasingly differentiated. Lilly has reported Phase 3 data for the triple agonist retatrutide, Roche and Zealand are co-developing the amylin analog petrelintide, Pfizer gained monthly GLP-1 and amylin candidates through Metsera, and Amgen, Boehringer Ingelheim, AstraZeneca and Hanmi are advancing their own agents. Regulators are expected to weigh lean-mass preservation, cardiovascular outcomes and long-term safety more heavily as more products seek approval.

Compounding remains a regulatory gray zone. A federal court has backed the FDA's tirzepatide shortage decision, yet personalized compounding under the 503A pathway continues, and regulators are watching marketing claims, dosing accuracy and product quality more closely.

Patent timing is the most important variable for regional revenue. Core semaglutide protection lapses across ten countries holding nearly half of the global obesity burden by the end of 2026, while U.S. and European exclusivity runs into the 2030s. That gap will produce a two-speed market in which branded pricing holds in high-income systems and generic economics dominate emerging markets, encouraging lifecycle strategies built on new formulations, combinations and outcome labels.

Approved GLP-1 weight-management supply is highly concentrated. Novo Nordisk and Eli Lilly supply nearly all approved branded volume, and their rivalry now centers on efficacy, oral formulations, manufacturing scale and price rather than on supply alone.

Over the forecast period, competitive advantage is expected to depend on four capabilities: superior weight loss with tolerable side effects, low-cost oral or monthly dosing, sufficient manufacturing capacity, and credible outcome data that justify payer coverage. Companies lacking one of these will find it difficult to win share against entrenched incumbents.

Partnerships remain the preferred entry route for challengers because building peptide and device capacity takes years. Licensing deals, acquisitions of clinical-stage biotech companies and contract manufacturing agreements are expected to continue as the market broadens beyond its first two leaders. Contract manufacturers with peptide and fill-finish capacity are gaining strategic importance as a result.

• Novo Nordisk A/S
• Eli Lilly and Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Zealand Pharma A/S
• Amgen Inc.
• AstraZeneca PLC
• Boehringer Ingelheim
• Innovent Biologics
• Hanmi Pharmaceutical
• Viking Therapeutics
• Structure Therapeutics
• Teva Pharmaceutical Industries
• Dr. Reddy's Laboratories
• Apotex Inc.

Market revenue is expected to almost triple from USD 34.0 billion in 2026 to USD 95.0 billion in 2034, equal to a 13.7% CAGR across 2026–2034. Growth will be volume-led, as treated patients multiply faster than revenue per prescription.

Oral agents and generic semaglutide are expected to grow faster than the market average, while branded injectables keep the largest revenue pool. Asia-Pacific and Latin America should gain regional share through 2034 because patent expiries convert large self-paying populations into treated patients, whereas North America will grow more slowly in value as negotiated and cash prices settle lower.

Value and volume will diverge. Prescription counts may rise several-fold, but average revenue per patient is likely to fall as cash-pay offers, Medicare negotiation and generics spread. Companies that combine lower manufacturing cost with clear outcome benefits will capture the most incremental value.

The main risks are payer pushback on lifelong therapy, safety signals from long-term use, compounding persistence and supply shocks. Upside could come from new indications, such as sleep apnea, osteoarthritis or heart failure, and from evidence that treatment reduces downstream healthcare costs.

Competitive structure is also likely to change by 2034. Novo Nordisk and Eli Lilly should remain the largest suppliers, but Pfizer, Roche, Amgen and other entrants are expected to launch differentiated agents late in the decade, and generic manufacturers will hold meaningful volume in markets where semaglutide patents have lapsed. End users will shift as well, with retail and online pharmacies retaining value leadership while specialty clinics expand their role in initiation and long-term monitoring.

The study supports strategy, investment and market-entry decisions across the full GLP-1 obesity value chain.